NYSE$CRL

Charles River Laboratories International Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Charles River Labs' second quarter results for 2023 were reported, with revenue of $1.06 billion and GAAP EPS of $1.89.

Charles River Laboratories reported second-quarter revenue of $1.06 billion, an 8.9% increase year-over-year. GAAP earnings per share were $1.89, while non-GAAP earnings per share were $2.69. The company has updated its 2023 guidance to reflect a solid first half performance.

  • Second-quarter revenue reached $1.06 billion, up 8.9% from the previous year.
  • GAAP earnings per share were $1.89, a decrease of 11.3% year-over-year.
  • Non-GAAP earnings per share were $2.69, a decrease of 2.9% year-over-year.
  • The company is narrowing its revenue growth and non-GAAP earnings per share outlooks for 2023.

Headline financials

Total Revenue

$1.06B

Previous: $973M+8.9%
EPS (adj)

$2.69

Previous: $2.77-2.9%
Free Cash Flow

$97M

Previous: $109M-11.3%
Net Income

$97M

Previous: $109M-11.3%
Operating Income

$165M

Previous: $187M-12.0%
Gross Profit

$23.9M

Previous: $13.9M+71.9%
Cash & Equivalents

$200M

Previous: $200M+0.1%
Total Assets

$7.77B

Previous: $7.53B+3.2%
Stock-Based Comp

$16.3M

Previous: $14.9M+9.0%

Revenue & EPS history

Charles River Labs · Revenue · Quarterly

$1.06B

Q2 2023+8.9%vs Q2 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Charles River Labs · $1.06B total across 3 segments · Q2 2023

  • Discovery & Safety Assessment
    $663M+12.1%
  • Research Models & Services
    $210M+12.6%
  • Manufacturing Solutions
    $187M-4.2%

Forward guidance

The company is narrowing its revenue growth and non-GAAP earnings per share outlooks to largely reflect its solid first-half financial performance and the successful implementation of mitigation efforts around NHP supply constraints.

Tailwinds

  • Solid first-half financial performance.
  • Successful implementation of mitigation efforts around NHP supply constraints.

Headwinds

  • Near-term demand trends as biopharmaceutical clients appear to be reprioritizing their pipelines and tightening R&D budgets.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+0.1%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+0.7%

Avg return

30 days after

47%

32 / 68 earnings

Positive

+18.4%

Q1 2025

Best reaction

-13.3%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.8%-9.0%-0.1%
Q4 2025-1.8%+3.1%-3.1%
Q3 2025-5.5%-5.0%+3.6%
Q1 2025+18.4%+24.0%+25.4%
Q4 2024+6.9%+10.4%+8.3%
Q3 2024+11.5%+17.0%+1.7%
Q2 2024-11.7%-15.1%-17.8%
Q1 2024-3.0%-1.0%-8.7%
Q4 2023+11.4%+11.2%+17.6%
Q3 2023-7.3%-7.0%+11.8%
Q2 2023+5.5%+5.2%-3.2%
Q1 2023+2.7%+1.0%+6.1%
Q4 2022-6.7%-9.0%-20.4%
Q3 2022+4.8%+9.0%+7.4%
Q2 2022-6.6%-9.4%-17.8%
Q1 2022-1.2%-8.9%-3.3%
Q4 2021-6.7%-6.1%-8.3%
Q3 2021-12.2%-13.4%-17.3%
Q2 2021-0.3%-0.4%+9.3%
Q1 2021+4.0%+3.2%-0.1%
Q4 2020+2.0%-1.1%-0.0%
Q3 2020+2.6%+7.0%+3.7%
Q2 2020+6.8%+7.3%+0.4%
Q1 2020+11.1%+12.0%+24.2%
Q4 2019+8.6%+11.9%-21.3%
Q3 2019-2.5%+1.1%+12.0%
Q2 2019-5.1%-10.3%-7.0%
Q1 2019-4.2%-4.1%-10.4%
Q4 2018+8.1%+9.0%+11.1%
Q3 2018+8.8%+6.8%+3.0%
Q2 2018-5.2%-6.6%-1.6%
Q1 2018+0.3%-1.0%+8.5%
Q4 2017+8.2%+6.0%+9.9%
Q3 2017-13.3%-14.3%-11.9%
Q2 2017-1.7%-0.2%+10.0%
Q1 2017-3.8%-2.3%+2.8%
Q4 2016+7.6%+7.3%+8.4%
Q3 2016-9.0%-5.1%-3.0%
Q2 2016-0.0%-3.1%-3.0%
Q1 2016+2.5%
Q4 2015+3.9%
Q3 2015+5.7%
Q2 2015+1.4%
Q1 2015-8.8%
Q4 2014+6.3%
Q3 2014-1.9%
Q2 2014+6.0%
Q1 2014-6.6%
Q4 2013-1.6%
Q3 2013-1.2%
Q2 2013+3.4%
Q1 2013-3.9%
Q4 2012+0.9%
Q3 2012-5.3%
Q2 2012+2.3%
Q1 2012+1.8%
Q4 2010-1.3%
Q4 2011-1.3%
Q3 2011-5.0%
Q2 2011-9.4%
Q1 2010-2.4%
Q1 2011-0.1%
Q4 2008-0.9%
Q3 2010-4.4%
Q3 2009-4.4%
Q2 2010+3.6%
Q4 2009+3.6%
Q2 2009+3.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro